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Background: The transactivating response (TAR) element of human immunodeficiency virus type 1 (HIV-1) is the
source of two functional microRNAs (miRNAs), miR-TAR-5p and miR-TAR-3p. The objective of this study was to
characterize the post-transcriptional regulation of host messenger RNAs (mRNAs) relevant to HIV-1 pathogenesis by
HIV-1 TAR miRNAs.
Results: We demonstrated that TAR miRNAs derived from HIV-1 can incorporate into host effector Argonaute
protein complexes, which is required if these miRNAs are to regulate host mRNA expression. Bioinformatic
predictions and reporter gene activity assays identified regulatory elements complementary and responsive to miR-
TAR-5p and miR-TAR-3p in the 3’ untranslated region (UTR) of several candidate genes involved in apoptosis and
cell survival. These include Caspase 8, Aiolos, Ikaros and Nucleophosmin (NPM)/B23. Analyses of Jurkat cells that
stably expressed HIV-1 TAR or contained a full-length latent HIV provirus suggested that HIV-1 TAR miRNAs could
regulate the expression of genes in T cells that affect the balance between apoptosis and cell survival.
Conclusions: HIV-1 TAR miRNAs may contribute to the replication cycle and pathogenesis of HIV-1, by regulating
host genes involved in the intricate balance between apoptosis and infected cell, to induce conditions that
promote HIV-1 propagation and survival.
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Endogenous miRNAs are generally exported as ~60 to 70
nucleotide (nt) miRNA precursors [1] from the nucleus to
the cytoplasm, where they are processed by the ribonucle-
ase III Dicer-TAR RNA-binding protein (TRBP) complex
[2-4] into ~21-24 nt mature miRNA products. The Dicer-
TRBP complex recruits the Argonaute (Ago) enzyme,
which is loaded with the duplex RNA [5-8]. After strand
dissociation, Ago can act on messenger RNAs (mRNAs),
that have complementary sequences to the loaded guide
miRNA, and block protein expression by repressing
mRNA translation or inducing mRNA degradation [9].
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reproduction in any medium, provided the orviral reverse transcriptase and subsequently into double
stranded DNA (dsDNA), prior its integration into the
human host genome. Viral transcription is initiated from
the 5’ long terminal repeat (LTR) promoter by the cellu-
lar RNA polymerase II. Unspliced and spliced RNAs are
further exported to the cytoplasm by the HIV-1 Rev pro-
tein, to be respectively packaged into virion particles or
translated into HIV proteins. Viral transcription is en-
hanced when the HIV Tat protein binds to the TAR, a
structured RNA element present at the 5’ end of all
RNA transcripts derived from the virus [10-12]. In the
absence of Tat, transcription is aborted and short
non-polyadenylated RNA transcripts encoding the
first ~60 nt of the HIV-1 RNA genome, containing
the 5’ end TAR element, are produced [13-15]. TAR
RNA structure analysis have shown some evolution-
ary links between members of different groups [16]
and a high degree of nucleotide sequence conserva-
tion between subtypes [17]. HIV-1 TAR RNA struc-
ture is highly conserved among different biologicalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tions when RNA interference is directed against the
viral TAR hairpin [20].
We previously reported TAR from the 5’ end LTR,
which resembles endogenous pre-miRNAs, as a source of
small non-coding regulatory RNAs. The TAR hairpin
motif is also present within the 3’LTR of full-length HIV
transcripts [17,21,22] but the adjacent polyadenylation sig-
nals that are used exclusively within the 3’ LTR context
may render the site less prone to cleavage by Dicer. We
identified and characterized two miRNAs, miR-TAR-5p
and miR-TAR-3p, that are derived from this element [23].
Similar miRNA sequences or small RNAs derived from
HIV-1 have also been reported by others [24-26]. Further-
more, cellular mRNAs that have sequences complemen-
tary to HIV-1 miRNAs in their 3’ UTRs, and therefore,
are potential regulatory targets of these viral miRNAs,
have been identified [27]. Indeed, a role has been sug-
gested for HIV-1 miRNAs in transcriptional repression
mediated either by the HIV-1 miR-N367 [26] or TAR
miRNAs binding to the LTR promoter [24,28]. In
addition, Klase et al. showed that TAR miRNA expres-
sion in TAR-expressing cells conferred resistance to
apoptosis, and suggested that both the ERCC1, and
IER3 genes, found to be targeted by TAR miRNAs in
their assays, might be link to the observed effect [29].
Similarly, a viral miRNA, miR-BART-5 derived from the
Epstein-Barr virus (EBV) [30], targets the mRNA of the
host cell p53 up-regulator of apoptosis (PUMA), to reduce
the likelihood of the EBV-infected cells from undergoing
apoptosis-induced cell death [31]. Since TAR miRNAs
have been recently detected in exosomes released from
HIV-1 infected cells, their distributions within the non-
infected cell population might be enhanced [32].
HIV-1 infects CD4+ T cells and apoptosis is known to
be a significant cause of HIV-1-infected, CD4+ T cell
death [33]. Many HIV-1 proteins are reported to regulate
apoptosis by interfering with or promoting specific pro-
or anti-apoptotic cellular components [33]. Although
HIV-1 can induce the apoptosis of infected CD4+ T lym-
phocytes by distinct pathways, i.e. “from without”, “from
within” or in trans [33,34], the precise mechanisms re-
main uncertain [35-37].
In this study, we examined the regulatory properties of
the TAR miRNAs to identify cellular targets involved in
the pathogenesis of HIV-1. We found that HIV-1 TAR
miRNAs target and modulate the expression of host cell
mRNAs for Caspase 8, an initiator protein of the extrin-
sic apoptosis pathway [38], the Aiolos and Ikaros, tran-
scription factors involved in hematopoiesis, immunity
and cell fate [39], and Nucleophosmin (NPM)/B23, a
multifunctional nucleolar protein [40]. Our findings sug-
gest that HIV-1 TAR miRNA-mediated regulation of
these genes could shift the delicate balance betweenapoptosis and the survival of infected cells, thereby cre-
ating a cellular environment favourable to the replication
and persistence of the virus.
Results
TAR miRNAs are incorporated into Argonaute protein
complexes
Argonaute proteins are the core components of the
RNA silencing complexes (RISC) and exert their repres-
sive effects on specific mRNAs that are targeted by small
RNA species, e.g. miRNAs or small interfering RNAs
(siRNAs). To determine if HIV-1 TAR miRNAs associated
with any of the Argonaute proteins, we immunoprecipitated
Flag-Ago protein from HEK 293 cultured cells stably
transfected with the previously described constructs, U6-
shNEG or U6-TAR [41] and overexpressing Flag-Ago 1, 2,
3 or 4 (Figure 1A). We analyzed immunoprecipitates by
Northern blot using a radiolabeled probe against miR-
TAR-3p and detected the mature miR-TAR-3p strand in
all Flag-Ago immunoprecipitates (Figure 1B, probe miR-
TAR-3p). The abundance of miR-TAR-3p in the precip-
itates correlated with the amounts of Ago protein
expressed and immunoprecipitated (Figure 1A). We
could not detected miR-TAR-5p in Northen Blot but
we detected it in Ago1 and Ago2 immunoprecipitates
when we used more sensitive RNAse protection assays
(RPA) (Additional file 1, probe −5/32). These results
suggest that TAR miRNAs could regulate host mRNA
expression through their association with Argonaute
effector complexes.
A proteomic-based approach to identify cellular mRNA
targets of HIV-1 TAR miRNAs
First, we used a proteomic-based approach to identify
genes regulated by the HIV-1 TAR miRNAs. We created
Jurkat cell lines that stably expressed either U6-shNEG
or U6-TAR constructs and confirmed the expression of
miR-TAR-5p and miR-TAR-3p (Additional file 2A) in
four TAR-expressing Jurkat cell lines (Jurkat-TAR-1 to
TAR-4) by RPA, using the −5/32 and 33/59 radiolabeled
probes respectively [23] (Additional file 2B). Cell cycle
regulation was assessed by flow cytometry and no differ-
ence was observed among Jurkat-TAR 1–4, the NEG-1
and wild-type (WT) Jurkat cell lines, suggesting that ex-
pression of HIV-1 TAR does not have cytotoxic effects
on Jurkat cells (Additional file 3).
Of four clones tested, Jurkat-TAR-3 cells expressed the
highest levels of TAR miRNA (Additional file 2B). When
compared to Jurkat-NEG-1 control cells by 2D-gel elec-
trophoresis and mass spectrometry, we found that
NPM/B23, a 294-amino acid protein with a predicted
isoelectric point of 4.78, was downregulated in TAR ex-
pressing cells (Figures 2A and 2B). A total of 6 spots


























































































































































Figure 1 HIV-1 TAR miRNAs are loaded into Argonaute complexes. Stable HEK 293 cells expressing Flag-Argonaute 1–4 proteins were
transfected with either U6-shNEG or U6-TAR or not (mock) for 48 hours. Protein samples were collected (input) and immunoprecipitated (IP) by
an anti-Flag antibody. After the last wash, ¼ of the IP sample was kept for protein analysis and ¾ for RNA analysis. All solutions were prepared
with DNA/RNA nuclease free water and contain protease and RNAse inhibitors. A) Western blot analysis of Argonaute (Ago) proteins from
transfected samples. Input and IP samples were separated on a 10% polyacrylamide gel and immunoblotted with anti-Flag antibody. B) Northern
blot of miRNAs expressed from U6-shNEG or U6-TAR transfected cells using probes against NEG-3p or miR-TAR-3p miRNAs. The probe against U6
RNA was used as a loading control for input and IP samples.
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and 2B), and were downregulated close to three-fold in
Jurkat-TAR-3 cells (Figure 2C). The different spots most
likely represented forms of NPM/B23 proteins that had
different post-translational modifications [42]. A similar
2D-gel electrophoretic analysis of the Jurkat-TAR-1 cell
line, which expressed lower levels of TAR miRNAs
(Additional file 2B), showed the expression of NPM/B23
protein was also downregulated, but to a lesser degree
(D.L.O., J.J.R and P.P., unpublished observations), suggestingthat TAR miRNAs regulate the expression of NPM/B23 in a
dose-dependent manner.
To verify that the downregulation of NPM/B23 ob-
served in the Jurkat-TAR cells was not specific to our
Jurkat cell model, we also transiently transfected HEK
293 cells. Along with U6-TAR and U6-NEG plasmids,
we used a psiSTRIKE-based vector expressing either
miR-TAR-5p or miR-TAR-3p in the form of a short hair-
pin RNA (shRNA) (U6-sh5p and U6-sh3p respectively;
Additional file 4A). These vectors were validated to
Figure 2 NPM/B23 protein expression is downregulated in
Jurkat cells stably expressing HIV-1 TAR. A) Two-dimensional gel
electrophoresis [isoelectric point (pI) range: 4 to 6.7] comparing
clones of stable Jurkat cell lines expressing U6-TAR (TAR-3) or U6-
shNEG (NEG-1). B) A region of the panel in A) is enlarged to show
spots of the downregulated NPM/B23 protein in TAR-3 cell line
(bottom left panel) compared to the control NEG-1 cell line (upper
right panel). The six (6) spots identified as NPM/B23 (see results for
details) are circled (TAR-3 panel). C) Proteomic analysis of the spots
identified in B) showed there was a 1.5 to 3-fold decrease in the
expression of the NPM/B23 protein in the Jurkat TAR-3 cell line,
compared to Jurkat NEG-1 cells.
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TAR-3p using sequence-specific sensor constructs
(Additional file 4B). Western blots revealed that NPM/
B23 expression was also downregulated in HEK 293
cells that expressed TAR miRNAs (Additional file 4C),
confirming our previous findings for NPM/B23 in
Jurkat cells.
A bioinformatic-based approach to identify cellular mRNA
targets of HIV-1 TAR miRNAs
We used an in silico approach, based on a previous ver-
sion (2008) of the miRTAR algorithm (http://mirtar.mbc.
nctu.edu.tw/), to search for human mRNAs that contain a
putative binding site(s) in their 3’ UTRs for HIV-1 miR-
TAR-5p and/or miR-TAR-3p. The algorithm generated a
list of several candidate mRNAs with potential binding
sites that could be recognized by miR-TAR-5p (Additionalfile 5) and/or miR-TAR-3p (Additional file 6). Minimal free
energy (MFE) was determined by miRTAR or the RNA
Hybrid algorithm (http://bibiserv.techfak.uni-bielefeld.de/
rnahybrid/) and candidate mRNAs with different MFEs
were selected and validated in reporter gene activity assays
(Figures 3A and 3B). The ability of each TAR miRNA to
downregulate mRNA containing putative miRNA binding
sites from the candidate genes was established by inserting
three copies of the candidate gene’s predicted miRNA
binding sites into the 3’UTR of the Renilla luciferase (Rluc)
gene and performing dual luciferase assays in HEK 293
cells for 48 hours (Figure 3B). Rluc expression was
downregulated for all the candidate miRNA binding sites
tested but no correlation could be established with the
level of down regulation and the calculated MFEs (D.L.O.,
J.J.R and P.P., unpublished observations). The Caspase 8,
Aiolos and Ikaros genes were selected for further investiga-
tions based on their level of regulation by TAR miRNAs,
i.e.downregulation compare to control, and their rele-
vance to HIV-1 pathogenesis.
The binding sites for HIV-1 TAR miRNAs in the 3’ UTR of
Caspase 8, Aiolos, Ikaros and NPM/B23 mRNAs are
functional
The 3’UTR of Caspase 8, Aiolos, Ikaros and NPM/B23
mRNAs were analyzed by using the RNA Hybrid algorithm
for the presence of binding sites to HIV-1 miR-TAR-5p
and miR-TAR-3p (Figures 4A-D). The functionality of
these binding sites was confirmed in HEK 293 cells by
transiently transfecting them with U6-TAR and Rluc con-
structs that contained complete or truncated versions of
the Caspase 8, Aiolos, Ikaros or NPM/B23 mRNA 3’UTRs
(Figure 4E). For all constructs, Rluc expression was
downregulated compared to control HEK 293 cells
transiently transfected with the Rluc constructs and
the U6-shNEG (Figure 4F). These results suggest a role
for TAR miRNAs in regulating the expression of these
genes through recognition of the miRNA binding ele-
ments located in their mRNA 3’UTRs.
The regulatory effects of TAR miRNAs on the reporter
gene activity assays containing the NPM/B23 mRNA
3’UTR was relatively modest (Figure 4E, NPM/B23,
~10% downregulation). This may be understandable
given the current biological understanding of miRNA
function and the limitations of assays available for func-
tional validation. A possible explanation is that putative
miRNA binding sites within the 5’UTR or ORF of NPM/
B23 mRNA could also contribute to the regulation of
NPM/B23 expression in vivo. However, when tested, the
5’UTR and ORF of NPM/B23 mRNA did not downregulate
the reporter gene activity in transiently transfected HEK
293 cells (Additional file 7). These data suggest that HIV-1
TAR miRNAs regulate NPM/B23 protein expression
through the recognition of regulatory elements located
Figure 3 HIV-1 TAR miR-TAR-5p and miR-TAR-3p target different subsets of host genes. A) Minimal free energy (MFE) was calculated for a
subset of mRNAs selected from the list produced by human miRTAR algorithm. B) HEK 293 cells were co-transfected with U6-shNEG (control) or
U6-TAR and a vector containing the Renilla luciferase (Rluc) reporter gene usptream of three copies (3X) of the natural TAR-miRNA binding sites
from the selected mRNAs (n = 1 to 3 experiments, in duplicate). Results are expressed as mean ± s.e.m.
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might be explained by accessibility restrictions [43]for the
TAR miRNAs on the NPM/B23 3’UTR fused to the Renilla
luciferase gene. However, it appears that in mammals, viral
miRNAs exert their regulatory effect using mostly the same
mechanism as cellular miRNAs, by targeting the 3’UTR of
mRNAs [44].
Caspase 8, Aiolos, Ikaros and NPM/B23 mRNA levels are
differentially regulated in TAR-expressing cell lines and
J-Lat cell lines
Cellular miRNAs normally exert their regulatory effects
by repressing mRNA translation and/or mRNA degrad-
ation. Therefore, we examined if the Caspase 8, Aiolos,
Ikaros and NPM/B23 mRNA levels were affected by the
concomitant expression of TAR miRNAs in Jurkat cells.
Quantitative RT-PCR analyses revealed that the Caspase
8, Ikaros and NPM/B23 mRNAs were less abundant in
the TAR-3 Jurkat cell line compared to control Jurkatcells (Figure 5A), suggesting a destabilization of these
mRNAs. In contrast, the levels of these mRNAs in the
TAR-1, TAR-2 and TAR-4 Jurkat cell lines, which expressed
lower levels of TAR miRNAs than TAR-3 (Additional file
2B), were similar to those observed in NEG-1 Jurkat cells
(Figure 5A). This finding suggests that the amount of
miRNAs produced from TAR, and incorporated into
silencing complexes in the TAR-1, TAR-2 and TAR-4
Jurkat cell lines was sufficient to regulate expression
of these genes through suppression of translation,
without destabilizing the mRNA. On the other hand,
Aiolos expression was regulated differently from the
other genes in the Jurkat-TAR-3 cell line. Instead of
being downregulated, Aiolos RNA was more abundant
in the TAR-3 Jurkat cells than any other cell lines
(Figure 5A). Whether or not this upregulation of
Aiolos gene in TAR-3 correlate with the high level of
TAR miRNAs expressed in this cell line (Additional
file 2B) is unknown.
miRNA : miRNA BS
miR-TAR-5p 3' AGUC     UAGACCAGA            UUGGUCUCUCU 
               |||     |||||| ||            |  ||||| ||
BS1095     5' ACAGUUGAUAUCUGG CUGUCCUUUUUAUAAUGCAGAGUGAG
miR-TAR-5p  3'  GGUCUAGACCAGAUUGGUCUCUCU  
                :||||  |||    : ::|:||||
BS1291      5' GUCAGACAUGGAAAUGGUGGGGAGAC
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miR-TAR-3p : miRNA BS
miRNA  3'  ACCCAAGGGA UCAAUCGGUCUCU  
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miRNA : miRNA BS
mir-TAR-3p  3' ACCCAAGG  GAUCAAUCGGUCUCU  
                 ||||||  |||||   |||||||
BS2095      5'  UGGUUCCAUCUAGUA  CCAGAGGC 
-28.8
Rluc/Target mRNA 3'UTR Reporter Constructs
Figure 4 The 3’ untranslated region of Caspase 8, Aiolos, Ikaros and NPM/B23 mRNAs are targeted by TAR miRNAs. A-D) Schematic of
the binding sites for HIV-1 miR-TAR-5p and/or miR-TAR-3p identified in the endogenous 3’UTR of Caspase 8, Aiolos, Ikaros and NPM/B23 mRNAs.
Panels show the predicted base pairing and minimal free energy (MFE) calculated for each putative TAR miRNA binding site. E) Schematic of the
constructs used for the dual luciferase assays, showing the Renilla luciferase (Rluc) reporter gene coupled to the complete or partial 3’ UTR of
each mRNA. F) HEK 293 cells were co-transfected with U6-shNEG (control) or U6-TAR and and the reporter constructs described in panel E, (n = 1
to 3 experiments, in duplicate). Results are expressed as mean ± s.e.m.
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cell lines were relevant to the whole virus, we examined
the expression of Caspase 8, Aiolos, Ikaros and NPM/B23
mRNAs in J-Lat T cells, which are Jurkat cell lines that
contain a full-length, latent HIV-1 provirus with an inte-
grated green fluorescent protein gene (GFP) replacing the
HIV-1 nef gene [45]. These cells are a well-known model
used in reactivation of HIV-1 latency and they express
short abortive TAR RNA transcripts [14] which are a sub-
strate for Dicer and a source of TAR miRNAs [23,24]. J-
Lat clones were selected based on a previously published
study showing that unstimulated J-Lat clone 6.3 produces
short transcripts containing TAR RNA in the amount of
~10 copies per cell [14]. We screened four J-Lat clones
where the integrated proviruses reacted differently to theepigenetic-modifying agents histone deacetylase (HDAC)
inhibitors and NF-kB/PKC activators (Additional file 8),
and compared the Caspase 8, Aiolos, Ikaros and NPM/
B23 expression to a WT Jurkat cell line.
The levels of the mRNAs encoding Caspase 8, Ikaros
and NPM/B23 were lower in J-Lat clones 6.3 and 9.2
compared to WT Jurkat cells, but similar to WT in J-Lat
clone 10.6 (Figure 5B). J-Lat clone 10.6 differs slightly
from the other J-Lat clones; it is more susceptible to
HDAC inhibitors (HDAC) and NF-kB/PKC activators,
compared to the other J-Lat clones (Additional file 8), as
demonstrated by a higher percentage of reactivation
i.e. GFP levels (Additional file 8). Similar to the Jurkat-
TAR-3 line, we detected the Aiolos mRNA at much higher



































































































































Figure 5 Caspase 8, Aiolos, Ikaros and NPM/B23 mRNA levels
are differentially regulated in Jurkat TAR cells and J-Lat clones.
A) mRNA expression of Caspase 8, Aiolos, Ikaros and NPM/B23 in
Jurkat TAR clones 1–4 and NEG-1. Relative abundance was
calculated by normalizing to GAPDH mRNA levels and the mRNA
expression in the NEG-1 cells for each gene was set to 1. B) mRNA
expression of Caspase 8, Ikaros and NPM/B23 in J-Lat clones 6.3, 9.2
and 10.6. Relative abundance was calculated by normalizing to α-
Tubulin RNA levels and the expression in the WT Jurkat cell line was
arbitrarily set to 1. C) mRNA expression of Aiolos in J-Lat cells.
Relative abundance was calculated by normalizing to α-Tubulin RNA
levels and the Aiolos expression in the WT Jurkat cell line was
arbitrarily set to 1.
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fold increase increased by ~19%, ~25% and ~12% J-Lat
clones 6.3, 9.2 and 10.6 respectively compared to WT
Jurkat. As the data were collected in non-activated J-Latcells, it is not clear how discrepancy between clones were
linked to mRNA level analyses. At this point, it was not
clear if HIV-1 TAR miRNAs were repressing the transla-
tion of Aiolos mRNA into protein.
Caspase 8, Aiolos, Ikaros and NPM/B23 protein expression
is altered in TAR-expressing cell lines and in J-Lat cell
lines
Because miRNAs are known to bind mRNAs and cause
an initial repression of mRNA translation [46], we ana-
lyzed the expression of the Caspase 8, Aiolos, Ikaros and
NPM/B23 proteins in Jurkat-TAR cells and J-Lat cell
lines by Western blotting. The regulation of these genes
at the protein level may have an important impact at dif-
ferent stages of the HIV-1 pathogenic cycle.
Caspase 8 protein expression was downregulated be-
tween 30% and 70% in the Jurkat-TAR cells versus the
negative control (Figure 6A). However, the extent of
downregulation did not correlate with the level of TAR
miRNA expression. For example, a 70% downregulation
of Caspase 8 was observed in TAR-3 and TAR-4, which
expressed the highest and the lowest amount of TAR
miRNAs, respectively, according to the RPA performed
on the Jurkat-TAR cell lines (Additional file 2B). The
presence of two binding sites with highly favourable
MFE values for miR-TAR-5p and miR-TAR-3p with their
binding sites (−25.4 kcal/mol and −37.0 kcal/mol re-
spectively; Figure 4A), suggested that Caspase 8 mRNA
is sensitive to TAR miRNA regulation. However, the
protein downregulation of Caspase 8 did not go above
70% and suggest that a basal level of Caspase 8 is re-
quired for cell survival and homeostasis. It is known
that, in response to an apoptotic stimulus, the activated
form of Caspase 8 protein is cleaved into smaller frag-
ments. We did not observe any active Caspase 8 fragments
on our immunoblots (D.L.O., J.J.R and P.P., unpublished
observations), suggesting a stimulus-independent mechan-
ism of downregulation.
Ikaros protein expression in Jurkat-TAR cell lines was
downregulated from 30% to 50% (Figure 6B, Ikaros
panels) depending on the cell line. As shown above for
Caspase 8, Ikaros downregulation does not seem to be TAR
mirna dose-dependent. NPM/B23 was also downregulated
in the TAR-2 and TAR-3 cell lines by 30% (Figure 6C). Un-
like Caspase 8 and Ikaros, NPM/B23 protein expression is
lower in Jurkat-TAR cell lines expressing more TAR
miRNAs (Figure 3C).
In contrast to the three other genes, but consistent
with the mRNA data, we saw increased levels of Aiolos
protein in the Jurkat-TAR cell lines (Figure 6B, Aiolos
panels), so we cannot exclude the possibility that the
TAR miRNAs were upregulating Aiolos gene expression.
We observed a higher molecular weight Aiolos protein
species in Jurkat-TAR-3 cells that was absent from the
Figure 6 Caspase 8, Aiolos, Ikaros and NPM/B23 protein expression is differentially regulated in Jurkat TAR-expressing and J-Lat
clones. Western blots of Caspase 8 (A and D), Aiolos and Ikaros (B and E) and NPM/B23 (C and F) protein expression in Jurkat TAR cell lines
(A-C) and J-Lat (C-F) cell lines. The relative abundance of the Caspase 8, Aiolos, Ikaros and NPM/B23 proteins were calculated by normalizing
to the expression of α-tubulin protein in each sample. Samples were separated by 10% (B, E) or 15% SDS-PAGE (A, C, D and F).
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Aiolos panels) and could be due to expression of the
longest isoform of Aiolos, called Aio-1 [47].
To determine if the integrated HIV-1 provirus had an
effect on the protein expression of the TAR-miRNA puta-
tive target genes, we monitored the levels of Caspase 8,
Aiolos, Ikaros and NPM/B23 proteins in J-Lat cell lines.
We saw a modest downregulation of Caspase 8 (~10% to
50%) and NPM/B23 (~10% to 40%) protein levels in J-Lat
cells compared to WT Jurkat cells (Figure 6D and 6F). Al-
though the Ikaros mRNA levels were downregulated
by ~75% in J-Lat 6.3 and by ~20% in J-Lat 9.2 and
10.6 J-Lat, the protein level was only slightly reduced
(~10% in J-Lat 9.2 and 10.6, nothing in other cell
lines) (Figure 6E, Ikaros panels). In contrast, we ob-
served an increase in Aiolos protein expression in all
the J-Lat cell clones tested (Figure 6E, Aiolos panels),
which correlated with the relatively high levels of
Aiolos mRNA detected in these cells (Figure 6B,
Aiolos panels).
In summary, the mRNA regulatory properties of TAR
miRNAs were similar, at the protein level, in the Jurkat-
TAR and J-Lat cell lines. In both models, we observed a
downregulation of Caspase 8 and NPM/B23 proteinlevels, and an upregulation of Aiolos protein expression
that was associated with HIV-1 TAR miRNA expression.
Together, these observations suggest that a latent form
of the HIV-1 virus generates TAR miRNAs that could
regulate expression of genes, at the protein level, and
could potentially be important for cell survival and affect
HIV-1 replication.
The ratios between proteins regulated by HIV-1 miRNAs
may play a role in apoptosis resistance of HIV-1 infected
cells
Apoptosis is an important hallmark of HIV-1 pathogen-
esis [33] and it is not clear how HIV-1 interacts with the
cellular machinery to promote cell survival or avoid
apoptosis. To examine the impact of the TAR miRNA
regulation of Caspase 8, Aiolos, Ikaros and NPM/B23
protein levels on apoptosis, we induced apoptosis in
both the Jurkat-TAR cells (Figure 7A) and the J-Lat cell
clones (Figure 7B and 7C) by treating with etoposide
and anti-fas CH11. In the cell, etoposide complexes with
topoisomerase II and DNA to cause double and single-
stranded DNA breaks that induce apoptosis through the
DNA repair pathway. Anti-fas CH11 is an antibody that
activates the CD95/Fas receptor and induces apoptosis
Figure 7 Expression of TAR and TAR miRNAs may not protect Jurkat cells from apoptosis. A) Apoptosis of Jurkat NEG-1 and Jurkat-TAR
cell clones 1, 2 and 3 was induced by treating with etoposide (100 μM) or CH11 anti-fas activating antibody (25 ng/ml) for 6 hours. Cells were
analyzed using a luminescent assay for Caspase 3 and 7 activity. Data are presented as fold increases of relative luminescent units compared to
cells treated with 1% DMSO. B and C) Apoptosis of J-Lat cell clones 6.3, 8.4 and 10.6 was induced by treatment with etoposide (100 μM) or CH11
anti-fas activating antibody (25 ng/ml) for 6 hours. B) Cells were lysed and proteins were separated on a 10% polyacrylamide gel and analyzed by
Western blot using antibodies against PARP-1 and α-tubulin. C) For Caspase 3 and 7 activities, the assay was performed according to the
manufacturer’s instructions and luminescence detection was assessed. The results of three (3) independent experiments are shown separately.
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vating the caspases. Resistance to one or other drug
might allow us to link the genes targeted by the TAR
miRNAs to the DNA damage response pathway or the
Fas receptor pathway.
Apoptosis was monitored by measuring the enzymatic
activity of the effector proteins Caspase 3 and 7, both ac-
tive with etoposide and CH11 treatments. We observed
either no difference (Figure 7A, TAR-1 and TAR-3) or a
slightly higher rate of apoptosis (Figure 7A, TAR-2) in
Jurkat TAR cell lines compared to the control cells
NEG-1, which express a shRNA under U6 promoter
transcription (U6-shNeg). Therefore, the downregulation
of NPM/B23 protein levels and upregulation of Aiolos
protein expressed in the Jurkat-TAR-3 cell line may notaffect the balance of the cells between survival and
apoptosis. Both the etoposide and CH11 apoptotic
agents induced apoptosis in WT Jurkat and J-Lat
cells, confirmed by the detection of cleaved Poly
[ADP-ribose] polymerase 1 (PARP-1) (Figure 7B), a
downstream target of Caspase 3, on immunoblots
[48]. However, all of the J-Lat clones had reduced
amounts of cleaved PARP-1 compared to WT Jurkat
cells (Figure 7B, clones 6.3, 8.4 and 10.6), indicating
a certain degree of resistance to apoptosis. Further-
more, J-Lat clones were more resistant to apoptosis
induced by DNA breaks than by CD95/Fas activation
as we observed almost complete cleavage of PARP-1
in J-Lat clones 6.3, 8.4 and 10.6 treated with CH11
(Figure 7B, lane 6, 9 and 12).
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lyzed using a Caspase 3/7 assay. After treating with
etoposide, J-Lat cell clones 6.3 and 8.4, but not 10.6, had
reduced caspase activity compared to treated WT Jurkat
(Figure 7C, etoposide, all panels). However, the J-Lat cell
lines, except for J-Lat clone 8.4, were more susceptible
than WT Jurkat cells to apoptosis when it was induced
by the anti-fas CH11 antibody. This finding is consistent
with the reduced amount of cleaved PARP-1 shown in
Figure 7B for the same clones.
Our results indicate that HIV-1 infected cells are more
resistant to apoptosis when it is induced by the DNA
damaging agent etoposide. These data suggest that when
an HIV-1 genome is integrated into the host DNA, sev-
eral host genes including Caspase 8, Ikaros, Aiolos and
NPM/B23 genes are regulated by the HIV-1 TAR
miRNAs. The downregulation Caspase 8, Ikaros and
NPM/B23 of, and the overexpression of Aiolos, may play
important roles in the cell fate after HIV-1 infection.
Discussion
HIV-1 regulates the expression of many host cell genes
during infection of human cells [49]. Dysregulation of
host genes occurs when viral molecules interact with cell
components, disrupt normal cellular pathways, recruit
host factors for viral replication or change the endogen-
ous miRNA profile of the cell [50-53]. Here, we report
that HIV-1 TAR miRNAs could be another mechanism
by which HIV-1 regulates the expression of host genes.
We demonstrated that miR-TAR-5p and miR-TAR-3p
were incorporated into Ago complexes, which contains
the effector components of miRNA-targeted RNA silen-
cing [23] in human cells [54] and is required for small
RNA species to mediate mRNA regulatory effects [5].
We established stable Jurkat cell lines expressing the
HIV-1 TAR miRNAs and we selected four lines that
showed variations in TAR miRNA expression levels.
Based on the premises that (i) miRNAs regulate mRNAs
in a dose-dependent manner [55], and that (ii) increased
miRNA levels would yield a stronger phenotype, the
Jurkat TAR-3 cell line was selected for further proteomic
analyses and NPM/B23 emerged as a top protein candi-
date downregulated by the HIV TAR miRNAs. The 2D-
gel analysis of a clonal population (i) circumvented a
relatively high background associated to poorly infected
cells, as previously described [56], and (ii) allowed us to
study a stable latently-infected cell population, in con-
trast with other early-infected cell studies [56,57]. This
approach, however, also has its intrinsic limitations, the
most important of which may be (i) the poor separation
of proteins from some areas of the gel, and (ii) a fold
change too small to justify mass spectrometry analyses.
A dual luciferase reporter assay was used to confirm
the host gene targets we identified in silico and tomonitor the 3’UTR-mediated regulation of the genes of
interest by the TAR miRNAs. The dual luciferase assay,
although powerful, has limitations, all of which can dif-
ferently influence the results [58]. These include the type
of cells studied, the length of the regulatory element
(e.g. natural 3’UTR versus 3X binding sites), the bind-
ing site accessibility and the architecture of the
miRNA:mRNA base pairing. Data should be interpreted
with caution, because modest reporter gene downregulation
(~20%) has been previously observed in assays where the
3’UTR tested was fused to luciferase genes [31,59],
even when the predicted binding sites had a free en-
ergy (ΔG) as low as −30,7 kcal/mol, expecting a much
stronger regulation [31].
Three of the four genes that we selected from our re-
porter gene activity data were downregulated by TAR
miRNAs expressed in the Jurkat cell model. Although
the protein levels of Caspase 8, Ikaros and NPM/B23
were downregulated to varying degrees in the Jurkat
cells expressing TAR and the J-Lat cell lines, TAR
miRNAs did not induce comparable changes at the
mRNA level. Therefore, although reduced mRNA levels
generally account for most of the decreased protein pro-
duction [60], it would be imprudent to rely exclusively
on mRNA levels when assessing the effects and import-
ance of TAR miRNAs in regulating host gene expression.
Hence, the relevance of our proteomic analysis of Jurkat
cells expressing TAR miRNAs that identified NPM/B23
as an mRNA/protein that is targeted by the HIV-1 TAR
miRNAs.
The Aiolos gene was upregulated when TAR was
expressed at a high level in the Jurkat cells or when the
HIV-1 was integrated in the cells as a provirus. The
upregulation of a gene upon miRNA binding has been
observed with small activating RNAs (saRNAs), which
are reported to enhance gene expression [61,62]. In
addition, a given miRNA binding site can mediate re-
pression in some 3’ UTRs, but not others [46], which
could also explain the result. The overall effect of the
TAR miRNAs on Aiolos expression may also involve
regulation at the transcriptional level and, because Aiolos
is a transcription factor, there may be complex feedback
loops involved. The TAR miRNA downregulatory effect
on Aiolos might be related to other stages of the HIV-1
pathogenesis or could occur in different cells types that
have not been tested in this study.
Apoptosis is known to be a significant cause of HIV-1-
infected, CD4+ T cell death. However, the molecular
mechanism determining the balance between cell sur-
vival and cell death remains unclear. Our results suggest
that the regulation of selected host mRNAs by TAR
miRNAs could influence the choice made by HIV-1
infected cells between survival and apoptosis. This could
be the result of a complex interplay involving the up- and
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proteins by the TAR miRNAs, and the secondary effects
on the cellular machinery. Furthermore, because HIV-1
infection is a multi-step process, these cell components
may be regulated differently throughout the course of the
infection. For instance, up-regulation of the pro-apoptotic
Caspase 8, which cleaves and activates other downstream
caspases, renders cells susceptible to apoptosis via Fas sig-
naling [63]. Caspase 8 is cleaved by the HIV-1 protease
into Casp8p41, a fragment strongly associated with apop-
totic, HIV-1 infected CD4+ T cells [64]. HIV-1 could,
for example, delay or prevent apoptosis through TAR
miRNA-mediated downregulation of Caspase 8 early in
the infection cycle, to ensure robust viral replication
and packaging.
Another downregulated gene was Ikaros (also called
IKZF1), which is the founding member of a family of
zinc finger transcription factors that also includes Aiolos
(also called IKZF3) [39]. Ikaros increases normal oxida-
tive stress-induced apoptosis in erythroid cells [65]. By
reducing the level of Ikaros protein in T cells, TAR
miRNAs could decrease apoptotic events that are associ-
ated with HIV-1 infection. However, because etoposide
treatment can shorten the half-life of Ikaros [66], we
cannot exclude the effect of etoposide on Ikaros as an
explanation for the resistance of the etoposide-treated
Jurkat TAR and J-Lat cells to apoptosis.
Upregulation of Aiolos expression could also potentially
reduce apoptosis of HIV-1 infected cells. Aiolos is a tran-
scription factor whose expression is restricted to lymphoid
lineages. Aiolos binds to the Bcl-2 promoter, and also in-
teracts with the Bcl-2 and Bcl-XL proteins [67,68] to en-
hance their stability and promote cell survival. Because a
high Aiolos mRNA and protein expressions seemed to
correlate with TAR miRNA levels and a resistance to
apoptosis, it may be related to survival in infected cells.
The effects we have seen, e.g. cell survival and resist-
ance to apoptosis, in TAR-expressing and J-Lat cells
lines may also be explained by the downregulation of
NPM/B23 protein. NPM/B23 is a major nucleolar, multi-
functional protein that has been reported to interact
with the HIV-1 proteins Tat and Rev [69,70] and with
many cellular components [40]. A down regulation of
NPM/B23 protein expression in the nucleolus could
modify protein interactions and disrupt HIV-1 nucleolar
Rev localization [71] to promote its interaction with
other cellular or viral components. In the acute phase of
HIV-1 infection, NPM/B23 expression is increased [69]
and its acetylated form is recruited, in a Tat-dependant
manner, to the HIV-1 LTR to enhance viral transactiva-
tion [72]. The targeting of NPM/B23 could be a mech-
anism used by the TAR miRNAs to limit the replication
of HIV-1 thereby facilitating the escape of virus-infected
cells from apoptosis and promoting latency stage.The present study should improve our understanding
of the regulation of host genes by viral miRNAs and the
potential outcomes. Because hundreds of mRNAs can be
targeted by a single miRNA, and miRNAs may act in
concert to regulate mRNA translation [46], we speculate
that the TAR miRNAs of HIV-1 have evolved to play a
key role in viral pathogenesis, most likely by promoting
conditions that favor HIV-1 replication in host cells. Fu-
ture studies will elucidate the molecular mechanisms by
which the HIV-1 miRNAs are produced and how they
regulate host gene expression, to determine their relative
importance in the HIV-1 replicative cycle and pathogen-
esis. These studies should provide key insights into how
HIV-1 viral miRNAs contribute to shaping the host re-
sponse to viral infection and identify new, potential targets
for development of novel and improved therapeutics treat
HIV-1.
Conclusions
HIV-1 TAR miRNAs may regulate cellular apoptosis
through the direct or indirect regulation of apoptosis-
related genes, including Caspase 8, Aiolos, Ikaros and
NPM/B23. The TAR miRNAs act through components of
the regulatory pathway for host miRNAs, including the
Ago complexes. HIV-1 miR-TAR-5p and miR-TAR-3p
may thus determine the success of viral replication by
regulating the balance between the survival and death
of HIV-1 infected cells.
Methods
DNA constructs
The psiSTRIKE vector (Promega) encoding a short hair-
pin against a deleted region of Firefly luciferase gene was
used as a negative control (U6-shNEG). The WT TAR
region (U6-TAR) and psiCHECK (Promega) reporter
construct encoding miR-TAR-5p (miR-TAR-5p sensor)
and miR-TAR-3p (miR-TAR-3p sensor) have been de-
scribed previously [23,41]. Vectors expressing short hair-
pin RNAs, encoding either miR-TAR-5p (U6-sh5p), or
miR-TAR-3p (U6-sh3p), were cloned using sh5p up and
down or sh3p up and down oligonucleotides into psiSTRIKE
vector.
Three copies (3X) of the individual, natural binding sites
of each selected mRNA target identified by bioinformatic
analysis were inserted downstream of the Rluc open read-
ing frame (ORF) into the XhoI/NotI restriction sites of a
psiCHECK vector. The complete or truncated 3’UTR re-
gion of Caspase 8 [ENSG00000064012, complete 1120
base pair (bp) cloned], Aiolos [ENSG00000161405, first
845 bp cloned], Ikaros [ENSG00000185811, first 2230 bp
cloned] and NPM/B23 mRNAs [ENSG00000181163,
319 bp cloned], as well as the 5’UTR and ORF of NPM/
B23 mRNA, were amplified by the polymerase chain reac-
tion (PCR), and then cloned into the XhoI/NotI restriction
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Mammalian cell culture
Jurkat and J-Lat (full length clones 6.3, 8.4, 9.2 and 10.6)
were obtained from Dr. Eric Verdin through the NIH
AIDS Research and Reference Reagent Program, Div-
ision of AIDS, NIAID. Cells were maintained in RPMI-
1640 medium supplemented with 10% fetal bovine
serum and 2 mM L-glutamine at 37°C in a humidified
incubator under 5% CO2. HEK 293 and HEK 293 Flag-
Ago 1, 2, 3, 4 cells [73] were grown in DMEM
supplemented with 10% fetal bovine serum, 1 mM so-
dium pyruvate, 2 mM L-glutamine at 37°C in a humidi-
fied incubator under 5% CO2. Jurkat NEG-1 and TAR
stable cell lines were established by transfection with ei-
ther U6-shNEG or U6-TAR linearized vectors respect-
ively, by electroporation and subsequent clonal selection
using selective agent G418. Positive clones were selected
for the presence and abundance of HIV-1 TAR miRNAs
by using RNase protection assays (RPA) with probes and
by methods previously described [23].
Western blot
Cells were harvested and lysed in RIPA buffer (50 mM
Tris–HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS,
0.5% Sodium Deoxycholate,1 mM EDTA, 1X protease
inhibitor cocktail) for 15 minutes on ice, and then
centrifuged for 10 min at 10,000 g (4°C). Ten (10)-70 μg
of protein were separated by 10-15% SDS-PAGE and
transferred to PVDF membranes. Membranes were
blocked in 5% non-fat milk then probed with primary
antibodies for NPM/B23 (sc-47725, Santa Cruz Biotechnol-
ogy), Caspase 8 (9746, Cell Signaling), Aiolos (sc-101982,
Santa Cruz Biotechnology), Ikaros (sc-13039, Santa Cruz
Biotechnology), Flag (F-3165, Sigma), α-tubulin (T6074,
Sigma), GAPDH (2118, Cell signalling) overnight at 4°C.
Anti-mouse or anti-rabbit were used as secondary anti-
bodies and (Santa Cruz Biotechnology) and chemilumines-
cent signal was revealed using ECL substrate (Pierce).
Immunoprecipitation
HEK 293 and HEK 293 Flag-Ago1, 2, 3 or 4 cell lines,
were grown to 60% confluency, then transfected with
U6-shNeg or U6-TAR. Forty-eight (48) hours later, cell
were lysed in IP buffer (50 mM Tris–HCl pH 8,0,
137 mM NaCl, 1% Triton X-100, 1X protease inhibitor
cocktail), and 3 mg of total lysate was incubated with
anti-Flag M2 affinity agarose gel beads (A2220, Sigma)
overnight in the presence of RNAse inhibitors. Beads
were washed three times for five min in IP buffer and
prior to the last wash, were divided as follows: one quar-
ter (¼) of the IP was resuspended in 20 μl of loading dye
containing β-mercaptoethanol and kept for Western blotanalysis and three quarters (¾) was resuspended in 20 μl
of nuclease-free water and kept for Northern Blot ana-
lysis. All samples were boiled for 10 minutes after resus-
pension, and the input (total lysate) was kept for protein
analysis and total RNA extraction.
Northern blot
Total RNA from inputs was extracted using Stat-60 re-
agent (Tel-Test, Inc) and RNA was collected from im-
munoprecipitates as described above, then separated by
denaturating 8% PAGE. RNA was transferred onto
Hybond-XL membrane (GE), UV crosslinked and hy-
bridized in with PerfecHyb Plus (Sigma) containing
radiolabeled [α-32P] ATP probes complementary to NEG
RNA, miR-TAR-3p and U6 RNA (See Additional file 9
for the oligonucleotide sequences).
Two-dimensional (2D) gel electrophoresis and proteomic
analysis
Briefly, proteins were extracted from four different cul-
tures of Jurkat NEG clone 1 and Jurkat TAR clone 3 in
7 M urea, 2 M thiourea, 3% 3-[(3-Cholamidopropyl)
dimethylammonio]-1-propanesulfonate (CHAPS), 20 mM
1,4-Dimercapto-2,3-butanediol, 5 mM Tris(2-carboxyethyl)
phosphine hydrochloride (TCEP) and precipitated using
the 2D clean-up kit (GE Healthcare). Two hundred (200)
μg of proteins was loaded onto a 24 cm Immobiline Dry
Strip (GE Healthcare) for the first gel dimension. The sec-
ond dimension was run on a 12% polyacrylamide gel and
gels were fixed overnight then stained with Sypro Ruby
(Invitrogen) for 5 h. Comparative analysis of the Jurkat
NEG-1 and Jurkat TAR-3 was performed using the
Progenesis software (Nonlinear Dynamics). Spots of inter-
est were excised from the gels and trypsinized prior mass
to spectrometry analysis. Peptide samples were separated
by online reverse-phase (RP) nanoscale capillary liquid
chromatography (nanoLC) and analyzed by electrospray
mass spectrometry (ES MS/MS). Mass spectra were ac-
quired using a data-dependent acquisition mode using the
Xcalibur software (version 2.0). All MS/MS samples were
analyzed using Mascot (version 2.2.0; Matrix Science).
Scaffold (version Scaffold-2_01; Proteome Software Inc.)
was used to validate MS/MS-based peptide and protein
identification. Details are available upon request.
Dual luciferase reporter gene activity assay
HEK 293 cells were co-transfected with U6-TAR vector
(50 ng; Promega) and a psiCHECK reporter construct
(500 ng) in which the Rluc reporter gene was upstream
of three copies (3X) of the natural binding site of se-
lected host mRNAs (n = 1 to 3 experiments, in dupli-
cate). All Rluc/Fluc ratios were normalized with ratios
from HEK 293 cells containing a psiNEG U6-shNEG
control construct.
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were also co-transfected with U6-shNEG, U6-TAR, U6-
sh5p or U6-sh3p (100–500 ng) and either the miR-TAR-5p
or miR-TAR-3p sensors, or a psiC-NPM/B23 5’UTR, ORF
or 3’UTR (0.5-50 ng per construct). Cells were harvested
24–48 hrs later and luciferase activities were measured as
previously described [23,74]. Results are expressed as
mean ± standard error of the mean (s.e.m.).
Reverse transcription and quantitative PCR analysis
RNA was treated with Turbo™ DNAse (Life Technolo-
gies) for 30 minutes at 37°C and reverse transcribed
(RT) with random primers and the M-MLV reverse
transcriptase enzyme (Invitrogen), according to the
manufacturer’s instructions. Quantitative PCR (qPCR)
using IQ™ SYBR® green supermix (Bio-Rad) and listed
primers sets (Additional file 9) was performed in a
C1000 thermal cycler with a CFX96 Real-Time system
(Bio-Rad). Data were collected using the Bio-Rad CFX
manager software v. 1.6 (Bio-Rad).
Induction of apoptosis
Jurkat WT and J-Lat cells were seeded, in triplicate, into
96-well plates and incubated in the presence of 1% v/v
DMSO, 25 ng/ml Human Anti-Fas activating antibody
(clone CH11, Millipore) or 100 nM Etoposide (Sigma)
for 6 hours. Caspase-3 and Caspase-7 activities were
detected using the Caspase-Glo 3/7 assay (Promega)
according to the manufacturer’s recommendations, or
the proteins were extracted from the cells and analyzed
by Western blotting using anti-PARP antibody.
Additional files
Additional file 1: HIV-1 TAR miRNA are loaded into Argonaute 1 and 2
complexes. RNase protection assay analyses of RNA extracted from anti-Flag
immunoprecipitates derived from HEK 293 cells expressing Flag-Argonaute
1 (Flag-Ago1) or Flag-Argonaute 2 (Flag-Ago2).
Additional file 2: Expression of TAR-derived miR-TAR-5p and miR-TAR-3p
in four (4) different TAR-expressing Jurkat cell lines. Consensus miR-TAR-5p:
miR-TAR-3p sequences from HIV-1 TAR TAR RNA and RNase protection
assays using probes against miR-TAR-5p and miR-TAR-3p for RNA extracted
from Jurkat TAR-expressing cell lines (clones TAR 1, 2, 3 and 4) and the
control (NEG-1).
Additional file 3: Cell cycle analysis for Jurkat TAR-expressing and NEG cell
lines. Analysis of the cell cycle by flow cytometry in Jurkat TAR-expressing cell
lines (Jurkat TAR 1, 2, 3 and 4) and in control cells (Jurkat WT and NEG-1)
using propidium iodide (PI).
Additional file 4: NPM/B23 protein expression is downregulated by
both miR-TAR-5p and miR-TAR-3p. Schematic, reporter assay and Western
blots showing U6-sh5p and U6-sh3p downregulated NPM/B23 in HEK
293 cells.
Additional file 5: miRTAR predictions for HIV-1 miR-TAR-5p targets. List
of the messenger RNAs targeted by miR-TAR-5p, based on miRTAR
predictions.
Additional file 6: miRTAR predictions for HIV-1 miR-TAR-3p targets. List
of the messenger RNAs targeted by miR-TAR-3p, based on miRTAR
predictions.Additional file 7: Both miR-TAR-5p and miR-TAR-3p regulate gene
expression through the 3’UTR of NPM/B23. Reporter gene assay showing
the regulation of NPM/B23 5’UTR, ORF and 3’UTR by the miR-TAR-5p or
miR-TAR-3p, when expressed individually from conventional stem-loop.
Additional file 8: Drug stimulation of J-Lat cell lines. Flow cytometry
analysis of J-Lat clones 6.3, 8.4, 9.2 and 10.6 stimulated with TNF-α, PMA,
prostatin, TSA, SAHA, valproic acid and HMBA for 18 hours.
Additional file 9: Oligonucleotide sequences. List of oligonucleotide
sequences used for cloning, PCR and as DNA probes.
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